Navigation Links
Bortezomib for salvage therapy against progressive myeloma

Despite the initial efficacy of these therapies against multiple myeloma (MM), relapse is invariably the rule. Bortezomib (Velcade, formerly PS-341, Millennium, USA) is a novel first-class agent that inhibits the proteasome, a // multicatalytic cellular enzyme whose activity entails several molecular mechanisms, including, in particular, the NF-kB pathway.

Currently, bortezomib, alone or in combination with dexamethasone and doxorubicin, is under investigation as first-line and maintenance therapy. However, previous studies on advanced disease included a mixture of patients with multiple and heterogeneous previous regimens. Therefore, in order to obtain more careful information about the efficacy and tolerability of this drug in more homogeneously and less heavily pre-treated patients, researchers from Italy focused on the effects of bortezomib on a selected cohort of MM patients who had progressive disease after previous treatments including exclusively AuSCT and thalidomide. They focused on the effects of bortezomib as third line treatment (second salvage therapy) in a very homogeneous group of MM patients induced by AuSCT and relapsed or refractory after thalidomide employed as second line treatment (first salvage therapy).

For the study to be published in the journal Leukemia Research (available online 18 August 2005), twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib without adjunct of steroids as third line therapy. Three patients died of progressive disease during the first 2 cycles with bortezomib. Eighteen patients received at least 2 cycles and were evaluated for response. According to EBMT criteria, 2 complete (negative immunofixation) and 7 partial remissions were achieved. Duration of response lasted from 2 to 14+ months. Grades 3?4 toxicities (thrombocytopeni a, leucopenia, peripheral neuropathy and vasculitis) were observed in 7 patients, but no patient interrupted the treatment due to side effects.

The study indicates that the use of bortezomib, in this specific setting, is generally safe and may be effective in a relevant proportion of cases. The authors conclude that bortezomib alone may induce high quality responses as third line salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated myeloma patients with progressive disease after autologous transplantation and thalidomide.
'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... ... "I had a terrible time trying to get my grandson to use his ... had a more child-friendly design, then children would be more likely to look forward ... avoid the need to deliver medication via a nebulizer mask. The design will not ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West ... January 1, 2017. The name change aligns the entire company with its ... health care quality. , “We are very proud of the achievements associated with ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... HARRISBURG, Pa. , Dec. 9, 2016 ... today announced temporary regulations for medical marijuana dispensaries under ... The Pennsylvania Bulletin , and are now available ... what is needed in the plan for operation; process ... the dispensary; as well as where the dispensary facilities ...
(Date:12/9/2016)... 2016  Forge Therapeutics, Inc. today announced a ... EVT, TecDAX, ISIN: DE0005664809) to advance its novel ... of bacterial infections including those caused by drug ... attractive antibacterial target for more than the past ... starting points has hampered its progress. Forge has ...
Breaking Medicine Technology: